Cognition and radiation therapy for brain metastases: A new paradigm to define;Cognition et radiothérapie dans les métastases cérébrales: un nouveau paradigme à définir

Bulletin du Cancer

Volumn 100, Issue 1, 2013, Pages 69-74

  Tallet, Agnès ^a,b   Dhermain, Frédéric ^c   Taillia, Hervé ^d,e   Ricard, Damien ^d   Mornex, Françoise ^f   Métellus, Philippe ^b,g  

^a INSTITUT PAOLI CALMETTES   (France)

^b Groupe de Reflexion Sur la Prise en Charge des Metastases Cerebrales GRPCMaC   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d University of Paris Descartes   (France)

^e Ecole du Val de Grace   (France)

^f CH Lyon Sud   (France)

^g TIMONE HOSPITAL   (France)

Author keywords

Brain metastases; Neurocognition; Whole brain radiation therapy

Indexed keywords

BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; COGNITIVE DEFECT; HUMAN; NEUROTOXICITY; REVIEW; STEREOTACTIC RADIOSURGERY;

EID: 84875203234     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1682     Document Type: Article

References (50)

1. Patchell R, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280:1485-9.
2. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295: 2483-91.
3. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.
4. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009; 27:78-84.
5. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007;25:1260-6.
6. Abe E, Aoyama H. The role of whole brain radiation therapy for the management of brain metastases in the era of stereotactic radio-surgery. Curr Oncol Rep 2012; 14:79-84.
7. Soussain C, Ricard D, Fike J, Psimaras D, Mazeron JJ, Delattre JY. Central nervous system complications of radiotherapy and chemotherapy. Lancet 2009;374: 1639-51.
8. Murray KJ, Scott C, Zachariah B, et al. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04. Int J Radiat Oncol Biol Phys 2000; 48:59-64.
9. Regine WF, Scott C, Murray KJ, Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group study 91-04. Int J Radiat Oncol Biol Phys 2001; 51: 711-7.
10. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 21:2529-36.
11. Herman MA, Tremont-Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol 2003;26:273-9.
12. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004; 22: 157-65.
13. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006; 24:1305-9.
14. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:1388-95.
15. Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 2008;71:64-70.
16. Shibamoto Y, Baba F, Oda K, et al. Incidence of brain atrophy and decline in mini-mental state examination score after whole-brain radiotherapy in patients with brain metastases: a prospective study. Int J Radiat Oncol Biol Phys 2008;72: 1168-73.
17. Corn BW, Moughan J, Knisely JP, et al. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. Int J Radiat Oncol Biol Phys 2008;71: 71-8.
18. Grosshans DR, Meyers CA, Allen PK, Davenport SD, Komaki R. Neurocognitive function in patients with small cell lung cancer. Cancer 2008; 112:589-95.
19. Welzel G, Fleckenstein K, Schaefer J, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 2008; 72: 1311-8.
20. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 10:1037-44.
21. Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 2011; 29: 279-86.
22. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:77-84.
23. Le Péchoux C, Laplanche A, Faivre-Finn C, et al. Prophylactic Cranial Irradiation (PCI) Collaborative Group. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol 2011;22:1154-63.
24. Soffietti R, Rudà R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008;20:676-84.
25. Suh JH, Chao ST, Vogelbaum MA. Management of brain metas-tases. Curr Neurol Neurosci Rep 2009; 9: 223-30.
26. Witgert ME, Meyers CA. Neurocognitive and quality of life measures in patients with metastatic brain disease. Neurosurg Clin N Am 2011;22: 79-85 (vii).
27. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011;12: 703-8.
28. Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995;33: 179-82.
29. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocog-nitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007;60: 277-83 (discussion 283-4).
30. Armstrong C, Ruffer J, Corn B, DeVries K, Mollman J. Biphasic patterns of memory deficits following moderate-dose partial brain irradiation: neuropsychologic outcomes and proposed mechanisms. J Clin Oncol 1995; 13:2263-71.
31. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 2004;90:1691-6.
32. Laukkanen E, Klonoff H, Allan B, Graeb D, Murray N. The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae. Int J Radiat Oncol Biol Phys 1988;14: 1109-17.
33. Twijnstra A, Boon PJ, Lormans ACM, Ten Velde GPM. Neuro-toxicity of prophylactic cranial irradiation in patients with small cell carcinoma of the lung. Eur J Cancer Clin Oncol 1987; 23:983-6.
34. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39: 789-96.
35. van Oosterhout AG, Boon PJ, Houx PJ, Ten Velde GP, Twijnstra A. Follow-up of cognitive functioning in patients with small cell lung cancer. Int J Radiat Oncol Biol Phys 1995;31:911-4.
36. Mahmood U, Kwok K, Regine WF, Patchell RA. Whole-brain irradiation for patients with brain metastases: still the standard of care. Lancet Oncol 2010;11: 221-2.
37. Weiss SE, Kelly PJ. Neurocognitive function after WBRT plus SRS or SRS alone. Lancet Oncol 2010; 11: 220-1.
38. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009;73: 1069-76.
39. Senzer N. Rationale for a phase III study of erythro-poietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation. Semin Oncol 2002;29(6 Suppl. 19):47-52.
40. DeAngelis LM, Posner JB. Side effects of radiation therapy. In: DeAngelis LM, Posner JB, eds. Neurologic complications of cancer, 2nd ed. New York:Oxford University Press, 2009, p. 551-5.
41. Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized controlled trial. J Clin Oncol 2009;27:3712-22.
42. Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 2007; 62: 515-20.
43. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-7.
44. Gondi V, Tolakanahalli R, Mehta MP, et al. Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:1244-52.
45. Ghia A, Tomé WA, Thomas S, et al. Distribution of brain metas-tases in relation to the hippocampus: implications for neurocognitive functional preservation. Int J Radiat Oncol Biol Phys 2007; 68:971-7.
46. Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihip-pocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 2010;95:327-31.
47. Marsch JC, Herskovic AM, Gielda BT, et al. Intracranial metasta-tic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients. Int J Radiat Oncol Biol Phys 2010;76:504-12.
48. Cameron HA, Gould E. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience 1994; 61: 203-9.
49. Lemaire V, Koehl M, Le Moal M, Abrous DN. Prenatal stress produces learning deficits associated with an inhibition of neuro-genesis in the hippocampus. Proc Natl Acad Sci USA 2000; 97: 11032-7.
50. Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike Jr. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res 2003; 63: 4021-7.